Antibody responses to DNA vaccination of horses using the influenza virus hemagglutinin gene.
Equine influenza virus infection remains one of the most important infectious diseases of the horse, yet current vaccines offer only limited protection. The equine immune response to natural influenza virus infection results in long-term protective immunity, and is characterized by mucosal IgA and serum IgGa and IgGb antibody responses. DNA vaccination offers a radical alternative to conventional vaccines, with the potential to generate the same protective immune responses seen following viral infection. Antigen-specific antibody isotype responses in serum and mucosal secretions were studied in ponies following particle-mediated delivery of hemagglutinin (HA)-DNA vaccination on three occasions at approximately 63-day intervals. One group of four ponies were vaccinated at skin and mucosal sites and the another group were vaccinated at skin sites only. All ponies were subjected to a challenge infection 30 days after the third vaccination. Skin and mucosal vaccination provided complete protection from clinical signs of infection, while skin vaccination provided partial protection; DNA vaccination provided partial protection from viral shedding. DNA vaccination generated only IgGa and IgGb antibody responses, which occurred with a higher frequency in the skin and mucosa vaccinated ponies. No mucosal IgA response was generated prior to challenge infection and IgA responses were only detected in those ponies which shed virus postchallenge. These results demonstrate that HA-DNA vaccination induces IgG(a) and IgG(b) antibody responses which are associated with protection in the absence of mucosal IgA responses. In addition, additional DNA vaccinations of mucosal sites increased protection and the frequency of seroconversion in ponies.
Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison 53706, USA. lunnp@svm.vetmed.wisc.edu
D P
DP
Lunn
G
G
Soboll
B R
BR
Schram
J
J
Quass
M W
MW
McGregor
R J
RJ
Drape
M D
MD
Macklin
D E
DE
McCabe
W F
WF
Swain
C W
CW
Olsen
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis*; D005260:Female; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000235:genetics* / Q000276:immunology*; D006734:Horse Diseases / Q000276:immunology* / Q000821:virology; D006736:Horses; D009980:Influenza A virus / Q000737:chemistry / Q000276:immunology / Q000302:isolation & purification; D007252:Influenza Vaccines / Q000235:genetics / Q000276:immunology*; D008297:Male; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*; D019444:Vaccines, DNA / Q000276:immunology*
D000914:Antibodies, Viral; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D007252:Influenza Vaccines; D019444:Vaccines, DNA